Abstract
1. The κ1 and κ2 opioid receptor agonists U-62066 (8 mg/kg, i.p.) and (-)-bremazocine (0.7mg/kg, i.v.), respectively, both exhibit anti- arrhythmic properties against adrenaline-induced dysrhythmias in rats. 2. In contrast, (+)-bremazocine has no effect on adrenaline-induced dysrhythmias. 3. The κ1 opioid receptor agonists U-50 488 (110 nmol) and [D-Ala2]- dynorphin A (20 nmol) and the κ2 opioid receptor agonist (-)-bremazocine (30 nmol) exhibit pro-arrhythmic properties following intracerebroventricular administration. 4. Prior administration of the κ opioid receptor antagonist nor-binaltorphimine doses i.c.v. (14 nmol), i.p. (10 mg/kg), completely abolishes the pro-arrhythmic (BNI, i.c.v., 14 nmol) as well as anti- arrhythmic (BNI, 10 mg/kg, i.p.) effects of the κ opioid receptor agonists. 5. Neither hexamethonium (10 mg/kg, i.v.) nor atropine (1 mg/kg, i.v.) have any effect on the anti-arrhythmic actions of the κ1 opioid receptor agonist U-62066 following systemic administration. 6. It is suggested that the anti- arrhythmic effects of U-62066 and (-)-bremazocine are associated with the activation of peripheral κ opioid receptors and do not depend on the activation of κ opioid receptors in the autonomic nervous system.
| Original language | English |
|---|---|
| Pages (from-to) | 716-723 |
| Number of pages | 8 |
| Journal | Clinical and Experimental Pharmacology and Physiology |
| Volume | 26 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 1999 |
Fingerprint
Keywords
- κ opioid receptors
- κ opioid receptors
- Dysrhythmias
ASJC Scopus subject areas
- Physiology
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Participation of central and peripheral κ1 and κ2 opioid receptors in arrhythmogenesis. / Lishmanov, Yury B.; Maslov, Leonid N.; Ugdyzhekova, Dina S.
In: Clinical and Experimental Pharmacology and Physiology, Vol. 26, No. 9, 1999, p. 716-723.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Participation of central and peripheral κ1 and κ2 opioid receptors in arrhythmogenesis
AU - Lishmanov, Yury B.
AU - Maslov, Leonid N.
AU - Ugdyzhekova, Dina S.
PY - 1999
Y1 - 1999
N2 - 1. The κ1 and κ2 opioid receptor agonists U-62066 (8 mg/kg, i.p.) and (-)-bremazocine (0.7mg/kg, i.v.), respectively, both exhibit anti- arrhythmic properties against adrenaline-induced dysrhythmias in rats. 2. In contrast, (+)-bremazocine has no effect on adrenaline-induced dysrhythmias. 3. The κ1 opioid receptor agonists U-50 488 (110 nmol) and [D-Ala2]- dynorphin A (20 nmol) and the κ2 opioid receptor agonist (-)-bremazocine (30 nmol) exhibit pro-arrhythmic properties following intracerebroventricular administration. 4. Prior administration of the κ opioid receptor antagonist nor-binaltorphimine doses i.c.v. (14 nmol), i.p. (10 mg/kg), completely abolishes the pro-arrhythmic (BNI, i.c.v., 14 nmol) as well as anti- arrhythmic (BNI, 10 mg/kg, i.p.) effects of the κ opioid receptor agonists. 5. Neither hexamethonium (10 mg/kg, i.v.) nor atropine (1 mg/kg, i.v.) have any effect on the anti-arrhythmic actions of the κ1 opioid receptor agonist U-62066 following systemic administration. 6. It is suggested that the anti- arrhythmic effects of U-62066 and (-)-bremazocine are associated with the activation of peripheral κ opioid receptors and do not depend on the activation of κ opioid receptors in the autonomic nervous system.
AB - 1. The κ1 and κ2 opioid receptor agonists U-62066 (8 mg/kg, i.p.) and (-)-bremazocine (0.7mg/kg, i.v.), respectively, both exhibit anti- arrhythmic properties against adrenaline-induced dysrhythmias in rats. 2. In contrast, (+)-bremazocine has no effect on adrenaline-induced dysrhythmias. 3. The κ1 opioid receptor agonists U-50 488 (110 nmol) and [D-Ala2]- dynorphin A (20 nmol) and the κ2 opioid receptor agonist (-)-bremazocine (30 nmol) exhibit pro-arrhythmic properties following intracerebroventricular administration. 4. Prior administration of the κ opioid receptor antagonist nor-binaltorphimine doses i.c.v. (14 nmol), i.p. (10 mg/kg), completely abolishes the pro-arrhythmic (BNI, i.c.v., 14 nmol) as well as anti- arrhythmic (BNI, 10 mg/kg, i.p.) effects of the κ opioid receptor agonists. 5. Neither hexamethonium (10 mg/kg, i.v.) nor atropine (1 mg/kg, i.v.) have any effect on the anti-arrhythmic actions of the κ1 opioid receptor agonist U-62066 following systemic administration. 6. It is suggested that the anti- arrhythmic effects of U-62066 and (-)-bremazocine are associated with the activation of peripheral κ opioid receptors and do not depend on the activation of κ opioid receptors in the autonomic nervous system.
KW - κ opioid receptors
KW - κ opioid receptors
KW - Dysrhythmias
UR - http://www.scopus.com/inward/record.url?scp=0032835331&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032835331&partnerID=8YFLogxK
U2 - 10.1046/j.1440-1681.1999.03115.x
DO - 10.1046/j.1440-1681.1999.03115.x
M3 - Article
VL - 26
SP - 716
EP - 723
JO - Clinical and Experimental Pharmacology and Physiology
JF - Clinical and Experimental Pharmacology and Physiology
SN - 0305-1870
IS - 9
ER -